Abstract #3660

Quantifying acrolein with MRS: a viable biomarker to assess location and severity of TBI

Nicole Vike¹, Jonathan Tang², Riyi Shi^1,2, and Joseph Rispoli^2,3

¹Basic Medical Sciences, Purdue University, West Lafayette, IN, United States, ²Biomedical Engineering, Purdue University, West Lafayette, IN, United States, ³Electrical and Computer Engineering, Purdue University, West Lafayette, IN, United States

Currently, only invasive methods exist to study the molecular effects of traumatic brain injury (TBI). By instead using magnetic resonance spectroscopy (MRS), a non-invasive, quantitative method can be used to safely assess the severity and location of injury. Acrolein, a biomarker of TBI, increases in rat brain tissue following TBI. Acrolein shows signature peaks downfield of water at 6.5 and 9.4 ppm. We have successfully measured whole-brain phantom-injected acrolein using Bruker 7T MRS sequences and determined T₁ for acrolein, using NMR, so MRS parameters can be adjusted to maximize acrolein signal. Quantifying acrolein with MRS could provide a viable method to assess injury location and severity.

This abstract and the presentation materials are available to members only; a login is required.

Join Here